

PATENT ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT																										
NATURE OF CONVEYANCE:	SECURITY AGREEMENT																										
CONVEYING PARTY DATA																											
<table border="1"> <thead> <tr> <th>Name</th> <th>Execution Date</th> </tr> </thead> <tbody> <tr> <td>Albany Molecular Research, Inc.</td> <td>04/11/2012</td> </tr> <tr> <td>AMRI Burlington, Inc.</td> <td>04/11/2012</td> </tr> <tr> <td>AMRI Bothell Research Center, Inc.</td> <td>04/11/2012</td> </tr> <tr> <td>AMRI Renesselaer, Inc.</td> <td>04/11/2012</td> </tr> </tbody> </table>		Name	Execution Date	Albany Molecular Research, Inc.	04/11/2012	AMRI Burlington, Inc.	04/11/2012	AMRI Bothell Research Center, Inc.	04/11/2012	AMRI Renesselaer, Inc.	04/11/2012																
Name	Execution Date																										
Albany Molecular Research, Inc.	04/11/2012																										
AMRI Burlington, Inc.	04/11/2012																										
AMRI Bothell Research Center, Inc.	04/11/2012																										
AMRI Renesselaer, Inc.	04/11/2012																										
RECEIVING PARTY DATA																											
<table border="1"> <tr> <td>Name:</td> <td>Wells Fargo Bank, National Association</td> </tr> <tr> <td>Street Address:</td> <td>One Boston Place</td> </tr> <tr> <td>Internal Address:</td> <td>18th Floor</td> </tr> <tr> <td>City:</td> <td>Boston</td> </tr> <tr> <td>State/Country:</td> <td>MASSACHUSETTS</td> </tr> <tr> <td>Postal Code:</td> <td>02108</td> </tr> </table>		Name:	Wells Fargo Bank, National Association	Street Address:	One Boston Place	Internal Address:	18th Floor	City:	Boston	State/Country:	MASSACHUSETTS	Postal Code:	02108														
Name:	Wells Fargo Bank, National Association																										
Street Address:	One Boston Place																										
Internal Address:	18th Floor																										
City:	Boston																										
State/Country:	MASSACHUSETTS																										
Postal Code:	02108																										
PROPERTY NUMBERS Total: 100																											
<table border="1"> <thead> <tr> <th>Property Type</th> <th>Number</th> </tr> </thead> <tbody> <tr> <td>Patent Number:</td> <td>5578610</td> </tr> <tr> <td>Patent Number:</td> <td>5581011</td> </tr> <tr> <td>Patent Number:</td> <td>5589487</td> </tr> <tr> <td>Patent Number:</td> <td>5663412</td> </tr> <tr> <td>Patent Number:</td> <td>5750703</td> </tr> <tr> <td>Patent Number:</td> <td>5994549</td> </tr> <tr> <td>Patent Number:</td> <td>6153754</td> </tr> <tr> <td>Patent Number:</td> <td>6201124</td> </tr> <tr> <td>Patent Number:</td> <td>6444824</td> </tr> <tr> <td>Patent Number:</td> <td>6448406</td> </tr> <tr> <td>Patent Number:</td> <td>6452011</td> </tr> <tr> <td>Patent Number:</td> <td>6458958</td> </tr> </tbody> </table>		Property Type	Number	Patent Number:	5578610	Patent Number:	5581011	Patent Number:	5589487	Patent Number:	5663412	Patent Number:	5750703	Patent Number:	5994549	Patent Number:	6153754	Patent Number:	6201124	Patent Number:	6444824	Patent Number:	6448406	Patent Number:	6452011	Patent Number:	6458958
Property Type	Number																										
Patent Number:	5578610																										
Patent Number:	5581011																										
Patent Number:	5589487																										
Patent Number:	5663412																										
Patent Number:	5750703																										
Patent Number:	5994549																										
Patent Number:	6153754																										
Patent Number:	6201124																										
Patent Number:	6444824																										
Patent Number:	6448406																										
Patent Number:	6452011																										
Patent Number:	6458958																										

CH \$4000.00 5578610

Patent Number:	6579885
Patent Number:	6613907
Patent Number:	6747039
Patent Number:	6797826
Patent Number:	6919458
Patent Number:	6949559
Patent Number:	6974872
Patent Number:	7022880
Patent Number:	7084152
Patent Number:	7163949
Patent Number:	7232908
Patent Number:	7235564
Patent Number:	7238704
Patent Number:	7238834
Patent Number:	7265116
Patent Number:	7307094
Patent Number:	7309789
Patent Number:	7328549
Patent Number:	7361636
Patent Number:	7378391
Patent Number:	7390906
Patent Number:	7149985
Patent Number:	7498345
Patent Number:	7498443
Patent Number:	7511013
Patent Number:	7538084
Patent Number:	7541357
Patent Number:	7553846
Patent Number:	7560561
Patent Number:	7612090
Patent Number:	7632807
Patent Number:	7674922
Patent Number:	7678915
Patent Number:	7691615
Patent Number:	7696165

	7696166
Patent Number:	7745619
Patent Number:	7781430
Patent Number:	7799756
Patent Number:	7842802
Patent Number:	7858798
Patent Number:	7863271
Patent Number:	7863452
Patent Number:	7656050
Patent Number:	8022220
Patent Number:	8039453
Patent Number:	8053428
Patent Number:	8067604
Patent Number:	8067605
Patent Number:	8101632
Patent Number:	8106070
Patent Number:	8106244
Patent Number:	8110681
Patent Number:	8124600
Application Number:	11697415
Application Number:	12598882
Application Number:	12598912
Application Number:	12252823
Application Number:	12417598
Application Number:	12253170
Application Number:	12917066
Application Number:	13211678
Application Number:	12898271
Application Number:	13352864
Application Number:	12522657
Application Number:	12466809
Application Number:	12351561
Application Number:	12176144
Application Number:	12828807
Application Number:	12828855

	12828890
Application Number:	12828955
Application Number:	13052171
Application Number:	12884650
Application Number:	12777728
Application Number:	12777776
Application Number:	13151992
Application Number:	13330989
Application Number:	13331814
Application Number:	12685516
Application Number:	12604491
Application Number:	12995771
Application Number:	12995776
Application Number:	12680285
Application Number:	61562753
Application Number:	13384050
Application Number:	13027850
Application Number:	61609064

CORRESPONDENCE DATA

Fax Number: (302)636-5454
 Phone: 202-408-3121 x2348
 Email: jpaterso@cscinfo.com

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent via US Mail.

Correspondent Name: Corporation Service Company
 Address Line 1: 1090 Vermont Avenue NW, Suite 430
 Address Line 4: Washington, DISTRICT OF COLUMBIA 20005

ATTORNEY DOCKET NUMBER:	173283
-------------------------	--------

NAME OF SUBMITTER:	Jean Paterson
--------------------	---------------

Total Attachments: 15

source=4-18-12 Albany Molecular-PT#page1.tif
 source=4-18-12 Albany Molecular-PT#page2.tif
 source=4-18-12 Albany Molecular-PT#page3.tif
 source=4-18-12 Albany Molecular-PT#page4.tif
 source=4-18-12 Albany Molecular-PT#page5.tif
 source=4-18-12 Albany Molecular-PT#page6.tif
 source=4-18-12 Albany Molecular-PT#page7.tif
 source=4-18-12 Albany Molecular-PT#page8.tif

PATENT
REEL: 028078 FRAME: 0230

source=4-18-12 Albany Molecular-PT#page9.tif
source=4-18-12 Albany Molecular-PT#page10.tif
source=4-18-12 Albany Molecular-PT#page11.tif
source=4-18-12 Albany Molecular-PT#page12.tif
source=4-18-12 Albany Molecular-PT#page13.tif
source=4-18-12 Albany Molecular-PT#page14.tif
source=4-18-12 Albany Molecular-PT#page15.tif

RECORDATION FORM COVER SHEET
PATENTS ONLY

To the Honorable Commissioner of Patents and Trademarks: Please record the attached original documents or copy thereof.

1. Name of conveying party(ies):

Albany Molecular Research, Inc.
AMRI Burlington, Inc.
AMRI Bothell Research Center, Inc.
AMRI Rensselaer, Inc.

Additional name(s) of conveying party(ies) attached? ☐ Yes ☒ No

3. Nature of conveyance:

- ☐ Assignment ☐ Merger
☒ Security Agreement ☐ Change of Name
☐ Other _____

Execution Date: April 11, 2012

2. Name and address of receiving party(ies)

Wells Fargo Bank National Association
Name: _____

Internal Address: 18th Floor

Street Address: One Boston Place

City: Boston State: MA Zip: 02108

Additional name(s) & address(es) attached? ☐ Yes ☒ No

4. Application number(s) or patent number(s):

If this document is being filed together with a new application, the execution date of the application is: _____

A. Patent Application No.(s)

See attached Exhibit A

B. Patent No.(s)

See attached Exhibit A

Additional numbers attached? ☒ Yes ☐ No

5. Name and address of party to whom correspondence concerning document should be mailed:

Name: _____

Internal Address: _____

Street Address: _____

City: _____ State: _____ Zip: _____

6. Total number of applications and patents involved: 83

7. Total fee (37 CFR 3.41).....\$ _____

- ☐ Enclosed
☐ Authorized to be charged to deposit account

8. Deposit account number: _____

(Attach duplicate copy of this page if paying by deposit account)

DO NOT USE THIS SPACE

9. Statement and signature.

To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document.

Lisa A. Cobbett

Name of Person Signing

Lisa A Cobbett

Signature

April 18, 2012

Date

Total number of pages including cover sheet, attachments, and documents: 15

Mail documents to be recorded with required cover sheet information to:
Commissioner of Patents & Trademarks, Box Assignments
Washington, D.C. 20231

PATENT AND TRADEMARK SECURITY AGREEMENT

This Patent and Trademark Security Agreement (this "Agreement"), dated as of April 11, 2012, is made by and among **ALBANY MOLECULAR RESEARCH, INC.**, a Delaware corporation ("AMRI"), **AMRI RENSSELAER, INC.**, a Delaware corporation ("AMRI Rensselaer"), **AMRI BURLINGTON, INC.**, a Massachusetts corporation ("AMRI Burlington"), and **AMRI BOTHELL RESEARCH CENTER, INC.**, a Delaware corporation ("AMRI Bothell") and together with AMRI, AMRI Rensselaer and AMRI Burlington, each a "Company" and collectively, the "Companies", and **WELLS FARGO BANK, NATIONAL ASSOCIATION** ("Wells Fargo").

Recitals

A. Companies and Wells Fargo are parties to a Credit and Security Agreement (as amended, supplemented or restated from time to time, the "Credit Agreement") dated the same date as this Agreement, setting forth the terms on which Wells Fargo may now or hereafter extend credit to or for the account of Companies.

B. As a condition to extending credit to or for the account of Companies, Wells Fargo has required the execution and delivery of this Agreement by each Company.

ACCORDINGLY, in consideration of the mutual covenants contained in the Loan Documents and herein, the parties hereby agree as follows:

1. Definitions. All terms defined in the Recitals hereto or in the Credit Agreement that are not otherwise defined herein shall have the meanings given to them in the Credit Agreement. In addition, the following terms have the meanings set forth below:

"Patents" means all of each Company's right, title and interest in and to patents or applications for patents, fees or royalties with respect to each, and including without limitation the right to sue for past infringement and damages therefor, and licenses thereunder, all as presently existing or hereafter arising or acquired, including without limitation the patents listed on Exhibit A.

"Security Interest" has the meaning given in Section 2.

"Trademarks" means all of each Company's right, title and interest in and to: (i) trademarks, service marks, collective membership marks, registrations and applications for registration for each, and the respective goodwill associated with each, (ii) licenses, fees or royalties with respect to each, (iii) the right to sue for past, present and future infringement, dilution and damages therefor, and (iv) licenses thereunder, all as presently existing or hereafter arising or acquired, including, without limitation, the marks listed on Exhibit B.

2. Security Interest. Each Company hereby irrevocably grants Wells Fargo a security interest (the "Security Interest") in all of its right, title and interest in and to the Patents and in the Trademarks to secure payment of the Obligations. As set forth in the Credit Agreement, the Security Interest is coupled with a security interest in substantially all of the personal property of each Company. This Agreement grants only the Security Interest herein described, is not intended to and does not affect any present transfer of title of any trademark registration or application and makes no assignment and grants no right to assign or perform any other action with respect to any intent to use trademark application, unless such action is permitted under 15 U.S.C. § 1060.

3. Representations, Warranties and Agreements. Each Company represents, warrants and agrees as follows:

(a) **Existence; Authority.** Each Company is a corporation duly organized, validly existing and in good standing under the laws of its state of incorporation, and this Agreement has been duly and validly authorized by all necessary corporate action on the part of such Company.

(b) **Patents.** Exhibit A accurately lists all patents and applications for patents owned by each Company as of the date hereof, and accurately reflects the existence and status of applications and letters patent pertaining thereto as of the date hereof. If after the date hereof, any Company owns any patents or patent applications not listed on Exhibit A, or if Exhibit A ceases to accurately reflect the existence and status of applications and letters patent pertaining to such patents and patent applications, then such Company shall within 60 days provide written notice to Wells Fargo with a replacement Exhibit A, which upon acceptance by Wells Fargo shall become part of this Agreement.

(c) **Trademarks.** Exhibit B accurately lists all trademarks, service marks, collective membership marks, registrations and applications for registration for each owned by each Company as of the date hereof and accurately reflects the existence and status of all trademarks, service marks, collective membership marks, registrations and applications for registration for each as of the date hereof; provided, however, that Exhibit B need not list common law marks (i.e., Trademarks for which there are no applications or registrations) which are not material to such Company's or any Affiliate's business(es). If after the date hereof, any Company owns any trademarks, service marks, collective membership marks, registrations and applications for registration for each not listed on Exhibit B (other than common law marks which are not material to such Company's or any Affiliate's business(es)), or if Exhibit B ceases to accurately reflect the existence and status of applications and registrations pertaining to the trademarks, service marks, collective membership marks, registrations and applications for registration for each, then such Company shall within 60 days provide written notice to Wells Fargo with a replacement Exhibit B, which upon acceptance by Wells Fargo shall become part of this Agreement.

(e) **Title.** Each Company has good and marketable title to each applicable Patent and each Trademark listed on Exhibits A and B, free and clear of all Liens except Permitted Liens. Each Company (i) will have, at the time such Company acquires any rights in Patents or Trademarks hereafter arising, good and marketable title to each such Patent or Trademark free and clear of all Liens except Permitted Liens, and (ii) will keep all Patents and Trademarks free and clear of all Liens except Permitted Liens.

(f) **No Sale.** Except as permitted in the Credit Agreement, no Company will assign, transfer, encumber or otherwise dispose of the material Patents or Trademarks, or any interest therein, without Wells Fargo's prior written consent.

(g) **Defense.** Each Company will at its own expense and using commercially reasonable efforts, protect and defend the material Patents and Trademarks against all claims or demands of all Persons other than those holding Permitted Liens.

(h) **Maintenance.** Each Company will at its own expense maintain the Patents and the Trademarks to the extent reasonably advisable in its business including, but not limited to, filing all applications to obtain letters patent or trademark registrations and all affidavits, maintenance fees, annuities, and renewals possible with respect to letters patent, trademark registrations and applications therefor. Each Company covenants that it will not abandon nor fail to pay any maintenance fee or annuity due and payable on any material Patent or Trademark, nor fail to file any required affidavit or renewal in support thereof, without first providing Wells Fargo: (i) sufficient written notice, of at least 30 days, to allow Wells Fargo to timely pay any such maintenance fees or annuities which may become due on any material Patents or Trademarks, or to file any affidavit or renewal with respect thereto, and (ii) a separate written power of attorney or other authorization to pay such maintenance fees or annuities, or to file such affidavit or renewal, should such be necessary or desirable.

(i) **Wells Fargo's Right to Take Action.** If any Company fails to perform or observe any of its covenants or agreements set forth in this Section 3, and if such failure continues for a period of ten (10) calendar days after Wells Fargo gives such Company (or Administrative Borrower on such Company's behalf) written notice thereof (or, in the case of the agreements contained in subsection (h), immediately upon the occurrence of such failure, without notice or lapse of time), or if such Company notifies Wells Fargo that it intends to abandon a material Patent or Trademark, Wells Fargo may (but need not) perform or observe such covenant or agreement or take steps to prevent such intended abandonment on behalf and in the name, place and stead of such Company (or, at Wells Fargo's option, in Wells Fargo's own name) and may (but need not) take any and all other actions which Wells Fargo

may reasonably deem necessary to cure or correct such failure or prevent such intended abandonment.

(j) **Costs and Expenses.** Except to the extent that the effect of such payment would be to render any loan or forbearance of money usurious or otherwise illegal under any applicable law, Companies shall pay Wells Fargo on demand the amount of all moneys expended and all costs and expenses (including reasonable documented attorneys' fees and disbursements) reasonably incurred by Wells Fargo in connection with or as a result of Wells Fargo's taking action under subsection (i) or exercising its rights under Section 6, together with interest thereon from the date expended or incurred by Wells Fargo at the Default Rate.

(k) **Power of Attorney.** To facilitate Wells Fargo's taking action under subsection (i) and exercising its rights under Section 6, each Company hereby irrevocably appoints (which appointment is coupled with an interest) Wells Fargo, or its delegate, as the attorney-in-fact of each Company with the right (but not the duty) from time to time to create, prepare, complete, execute, deliver, endorse or file, in the name and on behalf of each Company, any and all instruments, documents, applications, financing statements, and other agreements and writings required to be obtained, executed, delivered or endorsed by any Company under this Section 3, or, necessary for Wells Fargo, after the occurrence and during the continuance of an Event of Default, to enforce its security interest in the Patents or Trademarks or to grant or issue any exclusive or non-exclusive license under the Patents or Trademarks to any third party, or to sell, assign, transfer, pledge, encumber or otherwise transfer title in or dispose of the Patents or Trademarks to any third party in accordance with the Credit Agreement. Each Company hereby ratifies all that such attorney shall lawfully do or cause to be done by virtue hereof. The power of attorney granted herein shall terminate upon the termination of the Credit Agreement as provided therein and the payment and performance of all Obligations (other than inchoate indemnification obligations).

4. **Debtor's Use of the Patents and Trademarks.** Each Company shall be permitted to license (to the extent permitted by the Credit Agreement), control and manage the Patents and Trademarks, including the right to exclude others from making, using or selling items covered by the Patents and Trademarks and any licenses thereunder, in the same manner and with the same effect as if this Agreement had not been entered into, so long as no Event of Default occurs and remains uncured.

5. **Events of Default.** Each of the following occurrences shall constitute an event of default under this Agreement (herein called "Event of Default"): (a) an Event of Default, as defined in the Credit Agreement, shall occur; or (b) any Company shall fail promptly to observe or perform any covenant or agreement herein binding on it and such failure continues for a period of 15 days after the earlier of (i) the date on which such failure shall first become known to or should have been known by any officer of such Company or (ii) the date on which written notice thereof is given to such Company by Wells Fargo; or (c) any of the

representations or warranties contained in Section 3 shall prove to have been incorrect in any material respect when made.

6. Remedies. Upon the occurrence and during the continuance of an Event of Default, Wells Fargo may, at its option, take any or all of the following actions in accordance with applicable law:

- (a) exercise any or all remedies available under the Credit Agreement;
- (b) sell, assign, transfer, pledge, encumber or otherwise dispose of the Patents and Trademarks; or
- (c) enforce the Patents and Trademarks and any licenses thereunder, and if Wells Fargo shall commence any suit for such enforcement, Company shall, at the request of Wells Fargo, do any and all lawful acts and execute any and all proper documents required by Wells Fargo in aid of such enforcement.

7. Miscellaneous. This Agreement can be waived, terminated or discharged, and the Security Interest can be released, only explicitly in a writing signed by Wells Fargo. This Agreement may only be modified or amended by a written agreement signed by all of the parties hereto. A waiver signed by Wells Fargo shall be effective only in the specific instance and for the specific purpose given. Mere delay or failure to act shall not preclude the exercise or enforcement of any of Wells Fargo's rights or remedies. All rights and remedies of Wells Fargo shall be cumulative and may be exercised singularly or concurrently, at Wells Fargo's option, and the exercise or enforcement of any one such right or remedy shall neither be a condition to nor bar the exercise or enforcement of any other. All notices to be given to Debtor under this Agreement shall be given in the manner and with the effect provided in the Credit Agreement. Wells Fargo shall not be obligated to preserve any rights any Company may have against prior parties, to realize on the Patents and Trademarks at all or in any particular manner or order, or to apply any cash proceeds of Patents and Trademarks in any particular order of application. This Agreement shall be binding upon and inure to the benefit of each Company and Wells Fargo and their respective participants, successors and assigns and shall take effect when signed by each Company and delivered to Wells Fargo, and each Company waives notice of Wells Fargo's acceptance hereof. Wells Fargo may execute this Agreement if appropriate for the purpose of filing, but the failure of Wells Fargo to execute this Agreement shall not affect or impair the validity or effectiveness of this Agreement. A carbon, photographic or other electronic reproduction of this Agreement or of any financing statement signed by a Company shall have the same force and effect as the original for all purposes of a financing statement. This Agreement shall be governed by the internal law of the State of New York without regard to conflicts of law provisions. If any provision or application of this Agreement is held unlawful or unenforceable in any respect, such illegality or unenforceability shall not affect other provisions or applications which can be given effect and this Agreement shall be construed as if the unlawful or unenforceable provision or application had never been contained herein or prescribed hereby. All representations and warranties contained in this Agreement shall

survive the execution, delivery and performance of this Agreement and the creation and payment of the Obligations.

**THE PARTIES WAIVE ANY RIGHT TO TRIAL BY JURY IN ANY
ACTION OR PROCEEDING BASED ON OR PERTAINING TO THIS
AGREEMENT.**

IN WITNESS WHEREOF, the parties have executed this Patent and
Trademark Security Agreement as of the date written above.

COMPANIES:

ALBANY MOLECULAR RESEARCH,
INC.

By: Lori M. Henderson
Name: Lori M. Henderson
Title: Vice President, General Counsel + Secretary

AMRI RENSSELAER, INC.

By: Lori M. Henderson
Name: Lori M. Henderson
Title: Vice President + Secretary

AMRI BURLINGTON, INC.

By: Lori M. Henderson
Name: Lori M. Henderson
Title: Vice President + Secretary

AMRI BOTHELL RESEARCH CENTER,
INC.

By: Lori M. Henderson
Name: Lori M. Henderson
Title: Vice President + Secretary

WELLS FARGO:

WELLS FARGO BANK, NATIONAL
ASSOCIATION

By: 

Name: Richard Mahtani

Title: Vice President

**EXHIBIT A
PATENTS**

Patent Description	Application Number	Patent Number	Application Date	Expiration Date*
Piperidine Derivatives	08/456,273	5,578,610	05/31/1995	11/26/2013
Aromatic Ketones and Processes for Their Preparation	08/455,991	5,581,011	05/31/1995	12/03/2013
Piperidine Derivatives and Process for Their Production	08/382,425	5,589,487	02/02/1995	12/31/2013
Aromatic Ketones	08/700,556	5,663,412	08/08/1996	06/24/2013
Piperidine Derivatives and Process for Their Production	08/382,649	5,750,703	02/02/1995	05/12/2015
Piperidine Derivatives and Process for Their Production	08/994,357	5,994,549	12/19/1997	06/24/2013
Process for Production of Piperidine Derivatives	08/576,068	6,153,754	12/21/1995	12/21/2015
Process for Production of Piperidine Derivatives	08/575,344	6,201,124	12/21/1995	12/21/2015
Process for Production of Piperidine Derivatives	09/634,983	6,444,824	08/09/2000	12/21/2015
Process for Production of Piperidine Derivatives	09/634,775	6,448,406	08/09/2000	12/21/2015
Process for Production of Piperidine Derivatives	09/634,169	6,452,011	08/09/2000	12/21/2015
Process for Production of Piperidine Derivatives	09/637,127	6,458,958	08/09/2000	12/21/2015
<u>Aryl and Heteroaryl Substituted Tetrahydroisoquinolines and Use Thereof</u>	<u>10/091,949</u>	6,579,885	<u>03/06/2002</u>	11/02/2020
Process for Production of Piperidine Derivatives with Microorganisms	09/754,786	6,613,907	01/04/2001	11/08/2020
<u>Aza-Benzothiopyranoindazoles with Antitumor Activity</u>	<u>10/096,421</u>	6,747,039	<u>03/12/2002</u>	11/14/2022
<u>Piperidine Derivatives and Process for Their Production</u>	<u>10/235,052</u>	6,797,826	<u>09/04/2002</u>	06/24/2013
<u>Process for Production of Piperidine Derivatives</u>	<u>10/212,829</u>	6,919,458	<u>08/05/2002</u>	12/21/2015
<u>Nitrogen Substituted Biaryl Purine Derivatives as Potent Antiproliferative Agents</u>	<u>10/680,832</u>	6,949,559	<u>10/07/2003</u>	01/28/2020
Process for Production of Piperidine Derivatives	10/212,854	6,974,872	08/05/2002	12/21/2015
Piperidine Derivatives and Process for Their Production	10/918,247	7,022,880	08/13/2004	06/24/2013
Novel 4-Phenyl Substituted Tetrahydroisoquinolines Therapeutic Use Thereof	09/902,845	7,084,152	07/11/2001	07/11/2021
4-Phenyl Substituted Tetrahydroisoquinolines and Use Thereof	09/704,306	7,163,949	11/02/2000	02/28/2021
Process for Production of Piperidine Derivatives with Microorganisms	10/638,841	7,232,908	08/11/2003	01/24/2022
<u>Vinorelbine Derivatives</u>	<u>11/003,583</u>	7,235,564	<u>12/03/2004</u>	12/03/2024
<u>Vinca Derivatives</u>	<u>11/003,560</u>	7,238,704	<u>12/03/2004</u>	12/02/2024
<u>Piperidine Derivatives and</u>	<u>11/250,924</u>	7,238,834	<u>10/14/2005</u>	06/24/2013

<u>Process for Their Production</u>				
<u>Aryl and Heteroaryl Substituted Tetrahydroisoquinolines and Use Thereof</u>	<u>10/917,801</u>	7,265,116	<u>08/13/2004</u>	11/02/2020
<u>Benzoxazole Carboxamides for Treating CINV and IBS-D</u>	<u>11/357,494</u>	7,307,094	<u>02/17/2006</u>	02/17/2026
<u>Novel 4-Phenyl Substituted Tetrahydroisoquinolines and Therapeutic Use Thereof</u>	<u>11/438,725</u>	7,309,789	<u>05/22/2006</u>	07/11/2021
<u>Process for Aseptic Vacuum Filling and Stoppering of Low Viscosity Liquids in Syringes</u>	<u>11/657,814</u>	7,328,549	<u>01/25/2007</u>	10/23/2026
<u>Novel Cyclosporin Alkynes and their Utility as Pharmaceutical Agents</u>	<u>11/232,293</u>	7,361,636	<u>09/21/2005</u>	07/11/2026
<u>Cyclosporin Alkyne Analogues and their Pharmaceutical Uses</u>	<u>11/232,360</u>	7,378,391	<u>09/21/2005</u>	11/09/2026
<u>Piperidine Derivatives and Process for Their Production</u>	<u>11/455,531</u>	7,390,906	<u>06/19/2006</u>	06/24/2013
<u>4-Phenyl Substituted Tetrahydroisoquinolines and Therapeutic Use Thereof</u>	<u>11/231,398</u>	7,419,985	<u>09/21/2005</u>	07/11/2021
<u>Process for Production of Piperidine Derivatives</u>	<u>10/943,276</u>	7,498,345	<u>09/17/2004</u>	10/17/2025
<u>Process for Production of Carebastine</u>	<u>10/944,309</u>	7,498,443	<u>09/17/2004</u>	10/10/2025
<u>Novel Cyclosporin Analogues and their Pharmaceutical Uses</u>	<u>11/232,292</u>	7,511,013	<u>09/21/2005</u>	09/21/2025
<u>Cyclosporins</u>	<u>10/802,013</u>	7,538,084	<u>03/16/2004</u>	06/10/2024
<u>Aryl- and Heteroaryl- Substituted Tetrahydroisoquinolines and Use Thereof to Block Reuptake of Norepinephrine, Dopamine, and Serotonin</u>	<u>11/183,066</u>	7,541,357	<u>07/15/2005</u>	11/07/2026
<u>2-Alkylbenzoxazole Carboxamides as 5HT3 Modulators</u>	<u>11/834,909</u>	7,553,846	<u>08/07/2007</u>	08/07/2027
<u>Process for Production of Piperidine Derivatives</u>	<u>11/123,275</u>	7,560,561	<u>05/06/2005</u>	12/21/2015
<u>Aryl and Heteroaryl Substituted Tetrahydroisoquinolines and Use Thereof</u>	<u>10/426,097</u>	7,612,090	<u>04/29/2003</u>	06/01/2023
<u>Novel Cyclosporin Alkynes and their Utility as Pharmaceutical Agents</u>	<u>12/046,854</u>	7,632,807	<u>03/12/2008</u>	09/21/2025
<u>Process for Production of Delta-9-Tetrahydrocannabinol</u>	<u>11/529,147</u>	7,674,922	<u>09/28/2006</u>	10/18/2028
<u>Process for Production of Piperidine Derivatives</u>	<u>11/521,820</u>	7,678,915	<u>09/15/2006</u>	12/21/2015
<u>Process for the Production of Piperidine Derivatives with Microorganisms</u>	<u>11/624,096</u>	7,691,615	<u>01/17/2007</u>	06/14/2021
<u>Use of Cyclosporin Alkyne Analogues For Preventing or Treating Viral-Induced Disorders</u>	<u>11/391,020</u>	7,696,165	<u>03/28/2006</u>	03/28/2026
<u>Use of Cyclosporin</u>	<u>11/391,023</u>	7,696,166	<u>03/28/2006</u>	03/28/2026

Alkyne/Alkene Analogues for Preventing or Treating Viral-Induced Disorders				
Vinca Derivatives	11/933,259	7,745,619	10/31/2007	12/03/2024
Benzoxazole Carboxamides for Treating CINV and IBS-D	11/934,523	7,781,430	11/02/2007	01/12/2027
Novel Processes For Stereoselective Synthesis of Trans ISAtx247	11/572,833	7,799,756	07/26/2005	10/07/2027
Vinorelbine Derivatives	12/331,691	7,842,802	12/10/2008	12/03/2024
Process for Production of Carebastine	12/356,277	7,858,798	01/20/2009	09/17/2024
2-Aminobenzoxazole Carboxamides as 5HT3 Modulators	11/835,178	7,863,271	08/07/2007	10/09/2028
Process for Production of Piperidine Derivatives	12/356,282	7,863,452	01/20/2009	09/17/2024
Aryl- And Heteroaryl-Substituted Tetrahydrobenzazepines And Use Thereof To Block Reuptake Of Norepinephrine, Dopamine And Serotonin	11/487,884	7,956,050	07/17/2006	03/15/2027
Process for Production of Piperidine Derivatives	12/483,002	8,022,220	<u>6/11/2009</u>	12/21/2015
Vinca Derivatives	11/854,186	8,039,453	09/12/2007	08/12/2029
Vinorelbine Derivatives	11/697,370	8,053,428	04/06/2007	01/12/2028
Process for Production of Carebastine	12/951,644	8,067,604	11/22/2010	09/17/2024
Process for Production of Piperidine Derivatives	12/956,601	8,067,605	11/30/2010	09/17/2024
5-Fuopyridinone Substituted Indazoles	12/522,709	8,101,632	01/09/2008	12/10/2028
Substituted Imidazoles As Bombesin Receptor Subtype-3 Modulators	12/311,541	8,106,070	04/02/2009	09/23/2028
Process For Production Of Delta-9-Tetrahydrocannabinol	13/108,651	8,106,244	05/16/2011	09/28/2026
Compounds For The Treatment Of Spinal Muscular Atrophy And Other Uses	12/293,268	8,110,681	12/30/2008	10/09/2027
5-HT3 Receptor Modulators, Methods Of Making, And Use Thereof	12/473,940	8,124,600	05/28/2009	05/28/2029





US Patent Applications:

Patent Application	Application/Serial Number	Application Date
Vinca Derivatives	11/697,415	04/06/2007

Aryl- And Heteroaryl-Substituted Tetrahydrobenzo-1,4-Diazepines And Use Thereof To Block Reuptake Of Norepinephrine, Dopamine, And Serotonin	12/598,882	05/08/2008
Aryloxy- And Heteroaryloxy-Substituted Tetrahydrobenzazepines And Use Thereof To Block Reuptake Of Norepinephrine, Dopamine, And Serotonin	12/598,912	05/08/2008
Aryl- And Heteroaryl-Substituted Tetrahydroisoquinolines And Use Thereof To Block Reuptake Of Norepinephrine, Dopamine And Serotonin	12/252,823	10/16/2008
Aryl- And Heteroaryl-Substituted Tetrahydroisoquinolines And Use Thereof To Block Reuptake Of Norepinephrine, Dopamine And Serotonin	12/417,598	04/02/2009
Aryl- And Heteroaryl-Substituted Tetrahydrobenzazepines And Use Thereof To Block Reuptake Of Norepinephrine, Dopamine And Serotonin	12/253,170	10/16/2008
Aryl- And Heteroaryl-Substituted Tetrahydrobenzazepines And Use Thereof To Block Reuptake Of Norepinephrine, Dopamine And Serotonin	12/917,066	11/01/2010
2,5-Methano- And 2,5-Ethano-Tetrahydrobenzazepine Derivatives And Use Thereof To Block Reuptake Of Norepinephrine, Dopamine, And Serotonin	13/211,678	08/17/2011
Epiminocycloalkyl[b] Indole Derivatives As Serotonin Sub-Type 6 (5-HT6) Modulators And Uses Thereof	12/898,271	10/05/2010
Benzofuro[3,2-c] Pyridine And Azepine Analogs As Serotonin Sub Type 6 (5-HT6) Modulators For The Treatment Of Obesity, Metabolic Syndrome, Cognition And Schizophrenia	13/352,864	01/18/2012
5-Pyridinone Substituted Indazoles	12/522,657	01/09/2008
2-Alkylbenzoxazole Carboxamides As 5HT3 Modulators	12/466,809	05/15/2009
(1-Azinone)-Substituted Pyridoindoles	12/351,561	01/09/2009
5-Pyridinone Substituted Indazoles	12/176,144	07/18/2008
Azinone-Substituted Azepino[b]Indole And Pyrido-Pyrrolo-Azepine MCH-1 Antagonists, Methods Of Making, And Use Thereof	12/828,807	07/01/2010
Azabicycloalkane-Indole And Azabicycloalkane-Pyrrolo-Pyridine MCH-1 Antagonists, Methods Of Making, And Use Thereof	12/828,855	07/01/2010
Azinone-Substituted Azapolycycle MCH-1 Antagonists, Methods Of Making, And Use Thereof	12/828,890	07/01/2010

Azinone-Substituted Azabicycloalkane-Indole And Azabicycloalkane-Pyrrolo-Pyridine MCH-1 Antagonists, Methods Of Making, And Use Thereof	12/828,955	07/01/2010
SGLT-2 Inhibitors	13/052,171	03/21/2011
Novel Antibacterial Compounds, Methods Of Making Them, And Uses Thereof	12/884,650	09/17/2010
Aryl, Heteroaryl, And Heterocycle Substituted Tetrahydroisoquinolines And Use Thereof	12/777,728	05/11/2010
7-([1,2,4]triazolo[1,5-a]pyridinyl-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydroisoquinoline And Use Thereof	12/777,776	05/11/2010
Glycine Transporter-1 Inhibitors, Methods Of Making Them, And Uses Thereof	13/151,992	06/02/2011
Piperazinone-Substituted Tetrahydro-carboline MCH-1 Antagonists, Methods Of Making, And Uses Thereof	13/330,989	12/20/2011
Tetrahydro-Azacarboline MCH-1 Antagonists, Methods Of Making, And Uses Thereof	13/331,814	12/20/2011
Process for Production of Piperidine Derivatives	12/686,516	1/13/2010
Synthesis of 2-Aminobenzoxazole Compounds	12/604,491	10/23/2009
<u>Crystalline Form of 6-[4S]-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine</u>	12/995,771	12/02/2010
<u>Processes for Preparing Tetrahydroisoquinolines</u>	12/995,776	12/02/2010
<u>Isoindoline Compounds for the Treatment of Spinal Muscular Atrophy</u> and Other Uses	12/680,285	04/29/2010
<u>Pyrido-/Azepino-Benzofuran and Pyrido-/Azepino-Benzothiophene MCH-1 Antagonists, Methods of Making, and Use Thereof</u>	<u>61/562,753</u>	<u>11/22/2011</u>
<u>5-HT3 Receptor Modulators, Methods of Making, and Use Thereof</u>	13/384,050	01/13/2012
<u>Process For Production Of Piperidine Derivatives</u>	13/207,850	08/11/2011
Novel Tetrahydroisoquinolines And Use Thereof To Block Reuptake Of Norepinephrine, Dopamine, And Serotonin	61/609,064	03/09/2012

EXHIBIT B
Trademarks

Trademark	Registration Number	Registration Date	Renewal Due Date
 <u>Albany Molecular Research, Inc.</u>	2,028,808	January 7, 1997	January 7, 2017
 <u>Albany Molecular Research, Inc.</u>	2,030,116	January 14, 1997	January 14, 2017
AMRI	3,360,935	December 25, 2007	December 25, 2013
	3,477,433	July 29, 2008	July 29, 2014
HYALURON	3,749,837	February 16, 2010	February 16, 2016
	3,497,634	September 9, 2008	September 9, 2014
BUBBLE-FREE FILLING	3,363,917	January 1, 2008	January 1, 2014
GET YOUR FILL	3,397,075	March 18, 2008	March 18, 2014